載入中
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
前收盤價
US$6.39
+US$0.21 · +3.40%
盤中時間採用ET。市場資料可能有所延遲。
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
日內區間
目前US$6.39
52週區間
目前US$6.39
盤中時間採用ET。市場資料可能有所延遲。
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
日內區間
目前US$6.39
52週區間
目前US$6.39
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 702.5萬 USD | 565.6萬 USD |
| 銷貨成本 | — | 213.3萬 USD | 170.7萬 USD | — | — |
| 毛利 | — | −213.3萬 USD | −170.7萬 USD | 702.5萬 USD | 565.6萬 USD |
| 研究與開發 | 1.34億 USD | 1.12億 USD | 4821.6萬 USD | 2840.2萬 USD | 2585.2萬 USD |
| 銷售、一般及管理費用 | 3610.7萬 USD | 3013.1萬 USD | 1248.3萬 USD | 800.7萬 USD | 615萬 USD |
| 營業費用 | 1.7億 USD | 1.4億 USD | 6069.9萬 USD | 3640.9萬 USD | 3200.2萬 USD |
| 利息收入 | 909.4萬 USD | 1535.9萬 USD | 228.2萬 USD | 56.5萬 USD | 1000 USD |
| 利息支出 | 48.9萬 USD | 14.2萬 USD | 18.7萬 USD | 6.5萬 USD | 3000 USD |
| 折舊和攤銷 | 179.9萬 USD | 213.3萬 USD | 170.7萬 USD | 105.1萬 USD | 58.6萬 USD |
| 營業利益 | −1.7億 USD | −1.43億 USD | −6240.6萬 USD | −2938.4萬 USD | −2634.6萬 USD |
| 淨利 | −1.61億 USD | −1.27億 USD | −6036.6萬 USD | −2889.3萬 USD | −2635萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1189.63萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM696.8萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF370.26萬0.00%954億 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM305.14萬0.05%64.1億 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO204.41萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB180.5萬0.02%108.2億 USD0.44%US$206.49+3.00%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP160.7萬0.06%26.06億 USD0.20%US$66.35+1.13%
Schwab U.S. Small-Cap ETFSCHA118.62萬0.01%218.24億 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBState Street SPDR S&P Kensho New Economies Composite ETFKOMPSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
